Nigerian pharmaceutical companies have significantly increased their investment in production capacity, allocating N29.26 billion in capital expenditure during the first nine months of the year. This represents an 81 percent increase compared to the same period last year. The surge in spending reflects efforts to meet rising domestic demand and reduce reliance on imported medicines.
The five publicly listed pharmaceutical manufacturers in Nigeria reported the investment as part of broader strategies to modernize their facilities and expand manufacturing capabilities. The funds were directed toward purchasing new machinery and upgrading existing production lines. Industry experts noted that the investment aligns with government initiatives to promote local manufacturing and improve healthcare access.
This marks a notable shift in the sector, which has historically struggled with limited production capacity and high import dependency. The increased investment comes amid growing pressure to ensure a stable supply of essential medicines, particularly in the wake of recent public health challenges. The government has also encouraged local production as a way to strengthen the healthcare system and reduce economic vulnerabilities linked to global supply chains.
